Cargando…
Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
RATIONALE & OBJECTIVE: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well estab...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568645/ https://www.ncbi.nlm.nih.gov/pubmed/37841418 http://dx.doi.org/10.1016/j.xkme.2023.100719 |
_version_ | 1785119395408773120 |
---|---|
author | Le, Dustin Chen, Jingsha Shlipak, Michael G. Ix, Joachim H. Sarnak, Mark J. Gutierrez, Orlando M. Schelling, Jeffrey R. Bonventre, Joseph V. Sabbisetti, Venkata S. Schrauben, Sarah J. Coca, Steven G. Kimmel, Paul L. Vasan, Ramachandran S. Grams, Morgan E. Parikh, Chirag Coresh, Josef Rebholz, Casey M. |
author_facet | Le, Dustin Chen, Jingsha Shlipak, Michael G. Ix, Joachim H. Sarnak, Mark J. Gutierrez, Orlando M. Schelling, Jeffrey R. Bonventre, Joseph V. Sabbisetti, Venkata S. Schrauben, Sarah J. Coca, Steven G. Kimmel, Paul L. Vasan, Ramachandran S. Grams, Morgan E. Parikh, Chirag Coresh, Josef Rebholz, Casey M. |
author_sort | Le, Dustin |
collection | PubMed |
description | RATIONALE & OBJECTIVE: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well established. STUDY DESIGN: Prospective observational cohort. SETTING & PARTICIPANTS: In the Atherosclerosis Risk in Communities) study, 948 participants were studied. EXPOSURES: The baseline plasma biomarkers of kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), soluble urokinase plasminogen activator receptor (suPAR), tumor necrosis factor receptor 1 (TNFR-1), tumor necrosis factor receptor 2 (TNFR-2), and human cartilage glycoprotein-39 (YKL-40) measured in 1996-1998. OUTCOME: Incident CKD after 15 years of follow-up defined as ≥40% estimated glomerular filtration rate decline to <60 mL/min/1.73 m(2) or dialysis dependence through United States Renal Data System linkage. ANALYTICAL APPROACH: Logistic regression and C statistics. RESULTS: There were 523 cases of incident CKD. Compared with a random sample of 425 controls, there were greater odds of incident CKD per 2-fold higher concentration of KIM-1 (OR, 1.49; 95% CI, 1.25-1.78), suPAR (OR, 2.57; 95% CI, 1.74-3.84), TNFR-1 (OR, 2.20; 95% CI, 1.58-3.09), TNFR-2 (OR, 2.03; 95% CI, 1.37-3.04). After adjustment for all biomarkers, KIM-1 (OR, 1.42; 95% CI, 1.19-1.71), and suPAR (OR, 1.86; 95% CI, 1.18-2.92) remained associated with incident CKD. Compared with traditional risk factors, the addition of all 6 biomarkers improved the C statistic from 0.695-0.731 (P < 0.01) and using the observed risk of 12% for incident CKD, the predicted risk gradient changed from 5%-40% (for the 1st–5th quintile) to 4%-44%. LIMITATIONS: Biomarkers and creatinine were measured at one time point. CONCLUSIONS: Higher levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with higher odds of incident CKD among individuals without diabetes. PLAIN-LANGUAGE SUMMARY: For people with diabetes or kidney disease, several biomarkers have been shown to be associated with worsening kidney disease. Whether these biomarkers have prognostic significance in people without diabetes or kidney disease is less studied. Using the Atherosclerosis Risk in Communities study, we followed individuals without diabetes or kidney disease for an average of 15 years after biomarker measurement to see if these biomarkers were associated with the development of kidney disease. We found that elevated levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with the development of kidney disease. These biomarkers may help identify individuals who would benefit from interventions to prevent the development of kidney disease. |
format | Online Article Text |
id | pubmed-10568645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105686452023-10-13 Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes Le, Dustin Chen, Jingsha Shlipak, Michael G. Ix, Joachim H. Sarnak, Mark J. Gutierrez, Orlando M. Schelling, Jeffrey R. Bonventre, Joseph V. Sabbisetti, Venkata S. Schrauben, Sarah J. Coca, Steven G. Kimmel, Paul L. Vasan, Ramachandran S. Grams, Morgan E. Parikh, Chirag Coresh, Josef Rebholz, Casey M. Kidney Med Original Research RATIONALE & OBJECTIVE: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well established. STUDY DESIGN: Prospective observational cohort. SETTING & PARTICIPANTS: In the Atherosclerosis Risk in Communities) study, 948 participants were studied. EXPOSURES: The baseline plasma biomarkers of kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), soluble urokinase plasminogen activator receptor (suPAR), tumor necrosis factor receptor 1 (TNFR-1), tumor necrosis factor receptor 2 (TNFR-2), and human cartilage glycoprotein-39 (YKL-40) measured in 1996-1998. OUTCOME: Incident CKD after 15 years of follow-up defined as ≥40% estimated glomerular filtration rate decline to <60 mL/min/1.73 m(2) or dialysis dependence through United States Renal Data System linkage. ANALYTICAL APPROACH: Logistic regression and C statistics. RESULTS: There were 523 cases of incident CKD. Compared with a random sample of 425 controls, there were greater odds of incident CKD per 2-fold higher concentration of KIM-1 (OR, 1.49; 95% CI, 1.25-1.78), suPAR (OR, 2.57; 95% CI, 1.74-3.84), TNFR-1 (OR, 2.20; 95% CI, 1.58-3.09), TNFR-2 (OR, 2.03; 95% CI, 1.37-3.04). After adjustment for all biomarkers, KIM-1 (OR, 1.42; 95% CI, 1.19-1.71), and suPAR (OR, 1.86; 95% CI, 1.18-2.92) remained associated with incident CKD. Compared with traditional risk factors, the addition of all 6 biomarkers improved the C statistic from 0.695-0.731 (P < 0.01) and using the observed risk of 12% for incident CKD, the predicted risk gradient changed from 5%-40% (for the 1st–5th quintile) to 4%-44%. LIMITATIONS: Biomarkers and creatinine were measured at one time point. CONCLUSIONS: Higher levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with higher odds of incident CKD among individuals without diabetes. PLAIN-LANGUAGE SUMMARY: For people with diabetes or kidney disease, several biomarkers have been shown to be associated with worsening kidney disease. Whether these biomarkers have prognostic significance in people without diabetes or kidney disease is less studied. Using the Atherosclerosis Risk in Communities study, we followed individuals without diabetes or kidney disease for an average of 15 years after biomarker measurement to see if these biomarkers were associated with the development of kidney disease. We found that elevated levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with the development of kidney disease. These biomarkers may help identify individuals who would benefit from interventions to prevent the development of kidney disease. Elsevier 2023-08-25 /pmc/articles/PMC10568645/ /pubmed/37841418 http://dx.doi.org/10.1016/j.xkme.2023.100719 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Le, Dustin Chen, Jingsha Shlipak, Michael G. Ix, Joachim H. Sarnak, Mark J. Gutierrez, Orlando M. Schelling, Jeffrey R. Bonventre, Joseph V. Sabbisetti, Venkata S. Schrauben, Sarah J. Coca, Steven G. Kimmel, Paul L. Vasan, Ramachandran S. Grams, Morgan E. Parikh, Chirag Coresh, Josef Rebholz, Casey M. Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
title | Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
title_full | Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
title_fullStr | Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
title_full_unstemmed | Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
title_short | Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
title_sort | plasma biomarkers and incident ckd among individuals without diabetes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568645/ https://www.ncbi.nlm.nih.gov/pubmed/37841418 http://dx.doi.org/10.1016/j.xkme.2023.100719 |
work_keys_str_mv | AT ledustin plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT chenjingsha plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT shlipakmichaelg plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT ixjoachimh plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT sarnakmarkj plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT gutierrezorlandom plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT schellingjeffreyr plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT bonventrejosephv plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT sabbisettivenkatas plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT schraubensarahj plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT cocasteveng plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT kimmelpaull plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT vasanramachandrans plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT gramsmorgane plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT parikhchirag plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT coreshjosef plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT rebholzcaseym plasmabiomarkersandincidentckdamongindividualswithoutdiabetes AT plasmabiomarkersandincidentckdamongindividualswithoutdiabetes |